Carisma Therapeutics to Participate in The Citizens JMP Life Sciences Conference
Rhea-AI Summary
Carisma Therapeutics Inc. (Nasdaq: CARM) is set to participate in The Citizens JMP Life Sciences Conference. The company, a clinical-stage biopharmaceutical firm specializing in innovative immunotherapies, will have its President and CEO, Steven Kelly, engage in a fireside chat on May 13th at 12:00 pm ET. The event will be webcasted and archived on the Investor Relations webpage.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, CARM declined 1.54%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
An audio webcast of the event will be available on the Company's Investor Events section of the Investor Relations webpage and will be archived for a limited time following the event.
About Carisma
Carisma Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on utilizing our proprietary macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. We have created a comprehensive, differentiated proprietary cell therapy platform focused on engineered macrophages and monocytes, cells that play a crucial role in both the innate and adaptive immune response. Carisma is headquartered in
Investors:
Shveta Dighe
Head of Investor Relations
investors@carismatx.com
Media Contact:
Julia Stern
(763) 350-5223
jstern@realchemistry.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/carisma-therapeutics-to-participate-in-the-citizens-jmp-life-sciences-conference-302135910.html
SOURCE Carisma Therapeutics Inc.
FAQ
When will Carisma Therapeutics participate in The Citizens JMP Life Sciences Conference?
Who will represent Carisma Therapeutics at the conference?
Where can I access the audio webcast of the event?
